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T-cell-mediated renal injury is a major cause of kidney
transplant rejection and renal failure; hence, understanding
T-cell migration within the kidney is important for preventing
renal injury. Interleukin (IL)-16 is a T-cell chemoattractant
produced by leukocytes. Here we measured IL-16 expression
in the kidney and its role in renal ischemia–reperfusion injury
induced by different conditions in several strains of mice.
IL-16 was strongly expressed in distal and proximal straight
tubules of the kidney. The IL-16 precursor protein was
cleaved to a chemotactic form in cultured tubular epithelial
cells. Inactivation of IL-16 by antibody therapy or IL-16
deficiency prevented ischemia–reperfusion injury as shown
by reduced levels of serum creatinine or blood urea nitrogen
compared to control mice. Further studies indicated that
fewer CD4-cells infiltrated the post-ischemic kidneys of
IL-16-deficient mice and that the protective effect of IL-16
antibody treatment was lymphocyte-dependent. Our results
suggest that IL-16 is a critical factor in the development of
inflammation-mediated renal injury and may be a
therapeutic target for prevention of ischemia–reperfusion
injury of the kidney.
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Renal ischemia–reperfusion injury (IRI) contributes to
function loss and long-term changes of kidney transplants,
and also is a common cause for acute renal failure or acute
kidney injury in native kidneys.1–3 To date, the pathogenesis
of renal IRI is not fully understood, but leukocyte infiltration,
particularly T cells, is currently considered as a crucial
pathogenic factor for renal tubular epithelial cell (TEC) and
endothelial cell death (apoptosis and necrosis).4–6 Indeed,
T-cell deficiency results in resistance to renal IRI, which could
be restored by the adoptive transfer of naive T cells in an
animal model.7 Targeting T cells, such as blocking T-cell
costimulating pathway CD28-B7, has been found to be
effective in the prevention of renal IRI.8–10 Therefore,
understanding of the molecular mechanisms by which
T cells are recruited and migrate to the post-ischemic renal
tissue is critical for the development of new therapeutic
strategy for patients with acute kidney injury and kidney
transplant rejection.
Interleukin (IL)-16 was first identified as a CD8þ
lymphocyte-producing T-cell chemoattractant factor.11–13 So
far it has been found in a variety of leukocytes and in some
non-immune cells (that is, fibroblasts, lung epithelial cells,
and brain cells).14,15 The secreted mature form of IL-16 is
released from pre-formed IL-16 protein (pro-IL-16) by
cleavage of caspase-3.16,17 Although the biological functions
of IL-16 are not completely known, its chemotactic activity
seems the most prominent, and more importantly it does not
require earlier activation of target cells (for example, T cell
and monocyte)18–21 or connective tissue matrices.11 Thus,
IL-16 may act as an initial chemokine for recruitment of
leukocytes in the development of local inflammation. Indeed,
a recent study indicates that in the animal model of
peripheral ischemia, the contribution of CD8þ infiltrate to
the early phase of collateral developments depends on its
IL-16 production, which recruits CD4þ mononuclear cells.22
In this study, we have examined the expression of IL-16 in the
nephron and TEC cultures. Our results demonstrate that
constitutive expression of pro-IL-16 is strongly detected in
various segments of the nephron, including distal tubules,
glomerula, and proximal straight tubules in the medulla and
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chemotactic form of IL-16 in TEC cultures. Neutralization of
IL-16 by monoclonal antibody treatment results in the
reduction of renal IRI in a murine model.
RESULTS
Expression of IL-16 mRNA and protein in renal tissue and TEC
culture
The presence of IL-16 (mRNA and protein) was first
examined by reverse transcription-PCR and western blot.
As shown in Figure 1a, IL-16 mRNA was detected in RNA
samples from primary and cloned NG1.1 TECs as well as
naive kidney sections. The expression of IL-16 in the kidney
and TEC cultures was further confirmed by the presence of
its protein, indicated in western blot. As demonstrated in
Figure 1b, there was a prominent anti-IL-16 antibody-bound
protein in the protein extracts of TEC and kidney tissue,
which likely was pro-IL-16 protein. The specificity of this
antibody in the detection of IL-16 protein was confirmed by
western blot using protein extract from IL-16-deficient
kidneys, in which no pro-IL-16 protein was shown (Figure
1c). Furthermore, it was noted that the position of pro-IL-16
protein in TEC was different from that in kidney tissue in the
blot, indicating that the modification occurred to this protein
when the kidney cells were grown in a culture system in vitro.
In agreement with that, a small size of protein (B19 kDa)
was uniquely recognized by anti-IL-16 antibody in the
protein extracts of TEC cultures, indicating the presence of
a mature form of IL-16 from these TEC cultures, respectively.
Release of chemotactic IL-16 in TEC culture
To further evaluate whether the mature form of IL-16 in TEC
culture had chemotactic activity, the leukocyte chemotaxis to
protein extracts of TEC (primary and NG1.1 cells) vs naive
kidney tissue was examined by chemotaxis assay. As shown in
Figure 2, protein extracts from both primary and cloned
NG1.1 TECs had a significant chemotactic activity of IL-16 to
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Figure 1 | Expression of IL-16 mRNA and protein in renal tissue
and TEC culture. Total RNA or protein extract was prepared from
primary and cloned NG1.1 TEC cultures as well as spleens and
PBS-perfused kidneys of naive C57BL/6 (WT) or IL-16 knockout (KO)
mice. (a) The presence of IL-16 mRNA was determined by RT-PCR
with appropriate PCR cycle numbers. The GAPDH mRNA was
included as an internal control for amount of total RNA in each
sample. (b) IL-16 protein was detected by western blot with anti-IL-16
antibody, and b-actin was reprobed in the same blot with anti-b-actin
IgG antibody. (c) The specificity of anti-IL-16 antibody in the
detection of IL-16 protein was confirmed using IL-16-deficient kidney
tissue (KO) vs wild-type (WT) kidney tissue in western blot analysis.
The data are representative of three independent experiments.
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Figure 2 | Presence of chemotactic IL-16 in TEC cultures.
The leukocyte chemotaxis assay of IL-16 was determined by the
fluorescence-based method with the ChemoTx Disposable
Chemotaxis System. Protein extracts from cloned TEC NG1.1 TEC
(upper graph) or primary TEC (lower graph) from C57BL/B6 mice were
incubated with dye-labeled B6 splenocytes in the presence of control
IgG (open square) or anti-IL-16 IgG 2ml (open circle) for 4 h. The
migration was calculated as described in the Materials and Methods
section. The data are presented as mean±s.d. of triplicate
determinants in a typical experiment, which was repeated twice with
consistent results.
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syngeneic splenocytes. In control IgG-treated cell extracts, the
maximal migration was seen in a range of 0.1–10 mg ml1 of
protein extract, in which 39.6±3.2% of migration was
stimulated by 1 mg of protein extract of NG1.1 TEC or
42.9±3.1% by 1mg of protein extract of primary TEC,
whereas there was no chemotactic activity in the extracts of
naive kidney tissue (data not shown). The chemotactic
activity in these TEC extracts was significantly eliminated by
the presence of anti-IL-16 monoclonal antibody, indicating
the presence of chemotactic IL-16 in TEC cultures, but not in
naive kidney.
Expression of pro-IL-16 protein in different segments of
nephron
Renal expression of pro-IL-16 protein in naive kidney was
examined using immunohistochemical staining. All control
staining including IL-16-deficient kidney tissue was negative
(Figure 3a). The positive staining of pro-IL-16 was found in
whole naive kidney (cortex, outer and inner medulla), but
different segments of nephron had various levels of pro-IL-16
protein (Figure 3a). In the cortex region, the staining was
largely in contrast among different structures, in which the
strongest staining of pro-IL-16 was localized in distal
convoluted tubules, whereas the staining of this protein was
relatively faint in proximal convoluted tubules as well as in
the glomerula (Figure 3b and c). Staining in the medulla,
however, was moderate as compared to those in the distal
convoluted tubules, and was more or less the same among
various structures (Figure 3b and d). Very interestingly, pro-
IL-16 staining was different in proximal tubules in different
locations. As shown in Figure 3d, the levels of staining in the
proximal straight tubules in the outer medulla were higher
than those in the proximal convoluted tubules in the cortex,
whereas no remarkable difference was seen between distal
convoluted and straight tubules in these two locations.
Reduction of renal IRI by administration of anti-IL-16
antibody
Renal IRI could be induced in the uni-nephrectomized B6
male mice. First, we tested whether kidney injury resulted in
the release of IL-16. Levels of IL-16 protein in urine samples
were measured using enzyme-linked immunosorbent assay
and were collected after 24 or 48 h post-ischemia–reperfusion.
As shown in Figure 4a, a significant amount of IL-16 protein
was detected in the urine from mice with renal IRI. In the
urine from normal naive mice, no detectable amount of IL-16
was seen. In contrast, in mice with ischemic kidneys, IL-16
protein could reach to 2.58±1.37 or 1.43±0.75 ng ml1 in
the urine after 24 or 48 h post-renal IRI. However, because
urine samples were not suitable for chemotaxis assay, whether
urinary IL-16 had chemotactic activity was not known. To
further confirm the release of IL-16 from the kidneys after
renal IRI, the immunohistochemical staining of IL-16 was
performed in these kidneys. As shown in Figure 4b,
histological analysis with periodic acid-Schiff staining
showed the levels of renal IRI in the kidney, in which less
staining of IL-16 protein prevailed in all the damaged tubules
(necrosis or apoptosis) as compared to those in the intact
tubules. All these results suggest that it is possible that renal
injury may lead to the release of renal IL-16, which may act as
a chemoattractant.
To understand the pathogenic role of IL-16 in inflamma-
tion-mediated kidney injury, the protective effects of anti-IL-
16 monoclonal antibody therapy on kidney functions and
injury were examined in a B6 mouse model of renal IRI. After
48 h of reperfusion, sera were harvested, and serum creatinine
and blood urea nitrogen (BUN) were measured. As shown in
Figure 5, the function of kidneys was better maintained by
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Figure 3 | Immunohistology for pro-IL-16 protein in naive kidney.
PBS-perfused naive kidney was harvested from B6 mouse, followed
by fixed in 10% buffered formaldehyde, embedded in paraffin, and
then sectioned for immunohistochemical staining with polyclonal
rabbit anti-IL-16 antibody. (a) Representative control staining. The
control staining included the sections stained with normal IgG as
primary antibody or without primary antibody, and IL-16 KO kidney
tissue sections stained with anti-IL-16 antibody. (b) Brown color
staining indicated the presence of pro-IL-16 in different kidney
segments (cortex, outer and inner medulla) (low magnification).
(c, d) Representative image of cortex (proximal and distal convoluted
tubules, and glomerula) and outer medulla (proximal and distal
straight tubules, and collecting tubules) (high magnification). The
data are presented as a typical image from each examination, which
was repeated twice with consistent results.
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anti-IL-16 antibody therapy, indicated by lower levels of
serum creatinine and BUN in the mice treated with anti-IL-
16 antibody (clone 14.1, 100 mg per mouse). Serum creatinine
levels in anti-IL-16 IgG-treated mice were 37.0±7.1 mM,
which were significantly lower than 93.0±15.4 mM in the
control IgG group (P¼ 0.0015) (Figure 5a). The sham-
operated control was 24.0±2.5 mM. The beneficial effect of
neutralization of IL-16 on renal function was further
supported by similar data in the measurement of BUN in
the same groups of mice (18.0±4.2 mM in the anti-IL-16 IgG
group vs 35.0±7.4 mM in the control IgG group, P¼ 0.0279)
(Figure 5b). These data were further confirmed using IL-16
knockout (KO) mice. As shown in Figure 6, deficiency in IL-
16 expression in mice resulted in resistance to IRI, indicated
by lower levels of serum creatinine and BUN in KO mice as
compared to those in wild-type (WT) mice. Serum creatinine
levels in KO mice were 49.6±8.3 mM, which were significantly
lower than 148±15.4 mM in the WT group (P¼ 0.0024)
(Figure 6a). Similar data in the measurement of BUN were
seen in these mice (22.4±3.7 mM in the KO group vs
61±7.6 mM in the WT group, P¼ 0.0002) (Figure 6b).
The protection of renal function by anti-IL-16 antibody
therapy was further confirmed by the reduction of renal
tubular injury in these mice. As shown in Figure 7, less renal
injury was found in the kidneys of the mice that received
anti-IL-16 therapy compared to control kidneys, indicated by
22.7±2.8% of tubular necrosis/vacuolization in the anti-IL-
16 antibody-treated group as compared to 38.7±3.8% in the
control group (P¼ 0.0033). The basal levels of tubular
necrosis in sham-operated mice were 3.8±3.8%. Taken
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Figure 4 | Detection of IL-16 in urine and kidney of mice with
renal IRI. C57BL/6 male mice were subjected to renal
ischemia–reperfusion at 32 1C of body temperature for 45 min.
(a) IL-16 protein presented in the urine after renal IRI. Urine samples
were collected after 24 or 48 h after injury. The levels of IL-16 protein
were measured by ELISA kit. Data are presented as a typical result of
three separate ELISA assay. (b) Immunohistochemical staining of IL-16
in the kidney with IRI. Damaged kidney samples were collected after
48 h after injury and were stained for the presence of IL-16 by
immunohistochemitry. The density of brown color staining correlates
with the levels of pro-IL-16 protein in nephron, respectively.
(c) Tubular damage was determined by histological analysis with
periodic acid-Schiff staining in the same sections. The data are
presented as a typical image from each examination, which was
repeated at least twice with consistent results.
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Figure 5 | Protective effect of anti-IL-16 antibody therapy on
renal IRI in B6 mouse model. B6 mice were subjected to renal
ischemia–reperfusion at 32 1C of body temperature for 45 min, and
received either anti-IL-16 IgG or control IgG (in 200 ml of saline)
through inferior vena cava (IVC) injection. Sham-operated mice
(sham) were performed simultaneously. Sera were collected after 48 h
of reperfusion. Kidney function was determined by measurement of
serum creatinine and urea (BUN). (a) Serum creatinine levels. Data are
presented as mean±s.e.m. of 11 mice in each group (except five
mice in sham). P¼ 0.0015 (anti-IL-16 IgG vs control IgG). (b) BUN
levels. BUN was measured in the same sera. Data are presented as
mean±s.e.m. P¼ 0.0279 (anti-IL-16 IgG vs control IgG, n¼ 11).
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Figure 6 | Resistance to renal IRI in IL-16 knockout (KO) mice. Both
Balb/c (WT) and IL-16 KO (Balb/c background) mice were subjected to
renal ischemia-reperfusion at 34 1C of body temperature for 60 min.
Sera were collected after 48 h of reperfusion. Kidney function was
determined by measurement of serum creatinine and urea (BUN).
(a) Serum creatinine levels. Data are presented as mean±s.e.m.
of 12 mice in the WT control group or of nine mice in the KO group.
P¼ 0.0024 (KO vs WT). (b) BUN levels. BUN was measured in the same
sera. Data are presented as mean±s.e.m. P¼ 0.0002 (KO vs WT).
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together, these results indicate a critical role of IL-16, possibly
released from ischemic renal tissue, in the pathogenesis of
renal IRI.
Lymphocyte-dependent effectiveness of anti-IL-16 antibody
therapy in renal IRI
IL-16, a ligand for CD4 antigen, has been well characterized
as an important chemokine for T-cell migration. To evaluate
whether its chemotactic activity was a part of the mechanism
by which T cells (particularly CD4þ T cells) migrated to
ischemic kidney leading to renal injury, we first examined the
impact of IL-16 deficiency on migration of CD4þ cells to
post-ischemic kidneys. After 24 h of IRI, the total infiltrates
in ischemic kidneys of IL-16 KO mice were not significantly
different from those in WT mice (data not shown). However,
the percentage of CD4þ infiltrates in ischemic kidneys of
IL-16 KO mice (1.28±0.3%) was less than those in WT mice
(4.73±2.1%; P¼ 0.0082) (Figure 8). Second, we tested the
effect of anti-IL-16 antibody therapy on renal IRI in
lymphocyte-deficient mice. As shown in Table 1, NOD-scid/
scid mice (SCID) had a large deficiency in the number of
lymphocytes as compared to those in B6 mice. The most
notable deficiency in lymphocytes of SCID mice was CD4þ
T cells, which was only equal to 3% of the same phenotype in
B6 mice and was demonstrated to be a major pathogenic
mediator in renal IRI.23,24 If the pathogenic role of IL-16 in
renal IRI was dependent on its chemotactic activity on
lymphocytes, particularly CD4þ T cell, the protective effects
of anti-IL-16 antibody therapy on renal IRI would be reduced
in SCID mice as compared to the results in B6 mice
(Figure 5). Expectedly, induction of renal IRI in SCID mice
mainly depends on non-lymphocyte factors, whereas in B6
mice, both T cells or lymphocytes and non-lymphocyte
factors contribute to renal IRI. The antibody treatment and
the number of animals were the same in these two studies for
comparison. As shown in Figure 9, the reduction of renal IRI
by anti-IL-16 antibody in SCID mice was not as effective as
seen in B6 mice. The levels of serum creatinine in anti-IL-16
antibody-treated mice were 43±10 mM, which were not
statistically different from 72±23.5 mM in the control IgG-
treated group (P¼ 0.1405). In line with that, the levels of
BUN between these two groups of mice were also not
significantly different (22±4.8 vs 33±9.1 mM, P¼ 0.1331).
Our data may imply that the pathogenic role of IL-16 may
depend on lymphocytes, suggesting that the chemotactic
activity of this cytokine to lymphocyte effectors contributes
to the pathogenesis of renal IRI.
DISCUSSION
CD4þ T cells, particularly the helper T cells (Th1) subset, are
important mediators for renal IRI.23–26 However, the
mechanisms by which these cells are directed to migrate
into post-ischemic kidneys or nephrons remain largely
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Figure 7 | Less renal damage in anti-IL-16 antibody treated mice.
Tubular necrosis and vacuolization of renal samples were scored by
histological analysis with periodic acid-Schiff staining in a blinded
manner. Percentage of damaged tubules (necrosis and vacuolization)
in each section of kidney was counted at  400 magnification and
averaged for each mouse with no less than 20 viable fields per slide.
Data are presented as mean±s.e.m. in each group. P¼ 0.0033
(anti-IL-16 IgG vs control IgG; n¼ 8).
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Figure 8 | Less migration of CD4þ cells to post-ischemic kidneys
of IL-16 knockout (KO) mice. Both Balb/c (WT) and IL-16 KO (Balb/c
background) mice were subjected to renal ischemia–reperfusion at
34 1C of body temperature for 60 min. Infiltrating leukocytes from
ischemic kidneys were harvested by collagenases D (2 mg ml1)
digestion and gradient centrifugation after 24 h of reperfusion. The
percentage of CD4þ cells in isolated infiltrates was counted by FACS
analysis. (a) Percentage of CD4þ cells in a pair of IL-16 KO and WT
mice. (b) Data are presented as mean±s.d. of three mice in each
group (P¼ 0.0082, KO vs WT).
Table 1 | Lymphocyte deficiency in SCID mice
C57BL/6J (B6) SCID Proportion (%)a
Total splenocytes/
mouse ( 106)
98.1±11.5 14.7±1.2 15
CD4 T cells (%) 16.6±3.0 3.5±0.6 3
CD8 T cells (%) 9.0±2.6 4.8±2.3 8
B cells (%) 54.9±0.0 28.1±4.9 7.7
FACS, fluorescence-activated cell sorting; SCID, NOD-scid/scid.
The phenotype of lymphocytes was identified and counted by FACS analysis. CD4 T
cell, CD4+TCR+ cell; CD8 T cell, CD8+TCR+; B cell, B220+ cells. Data were presented as
mean±s.d. (n=4).
aThe proportion of lymphocytes in SCID mice was calculated as a percentage of
lymphocytes in B6 mice.
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unknown. Our results for the first time show the presence of
IL-16, a major T-cell chemoattractant factor15 in kidney
tissue. Under the stress of in vitro culture, the pro-IL-16 in
TEC can be cleaved to a chemotactic mature form of IL-16.
Release of IL-16 protein to urine is detected in mice with
ischemic kidneys, and neutralization of IL-16 with mono-
clonal antibody has a beneficial effect on the reduction of
renal IRI, which is lymphocyte-dependent.
To date, IL-16 has been mainly found in leukocytes
including CD4þ and CD8þ T cells,15 in which pro-IL-16 is
cleaved by caspase-3 into two active molecules, secreted
COOH-terminal peptide as mature IL-1617 and nuclear-
translocated NH2-terminal peptide.
27 However, the
regulations of IL-16 transcription (mRNA), translation
(pro-IL-16 protein), and post-translational modification
(caspase-3 cleavage) are different in various types of cells.
For example, IL-16 mRNA constitutively expresses in both
CD4þ and CD8þ T cells, but mature IL-16 is spontaneously
secreted from CD8þ T cells,13 whereas CD4þ T cells only
secrete IL-16 upon stimulation with antigen or mitogen.28
Similar to CD4þ T cells, we demonstrate that TEC
constitutively express IL-16 mRNA and pro-IL-16 protein
(Figures 1 and 3), which can be cleaved to chemotactic IL-16
upon exposure to in vitro environments (Figure 2), suggest-
ing that renal IL-16 may act as an initial chemokine for
leukocyte migration to stressed nephrons. In addition, it is
unknown whether caspase-3 cleaves pro-IL-16 to release its
chemotactic form in TEC, but western blot indicated a slower
mobility of pro-IL-16 protein from TEC cultures during the
electrophoresis in sodium dodecyl sulfate-polyacrylamide gel
electrophoresis as compared to that from naive kidney tissue
(Figure 1b), suggesting that removal of chemotactic peptide
(IL-16) from pro-IL-16 protein may lose the hydrophobic
residues and results in reduction of electronic charges on the
pro-IL-16 protein.
In renal IRI, a prominent pathological feature is tubular
injury, including both acute necrotic and apoptotic cell
death,29 which are induced by infiltrating leukocytes
including T cells as well as activation of complements.30–33
Indeed, in the mouse model, mice lacking T lymphocytes are
protected from renal IRI,31 and the injury can be restored
after the adoptive transfer of naive T cells.7 Furthermore,
numerous studies indicate that CD4þ T cells, particularly
interferon-g-producing Th1 phenotype, play a crucial role in
renal IRI.6,7,23,24,26,34
However, the molecular mechanisms underlying the
migration of CD4þ effector T cells to ischemic kidney to
damage the nephron are not fully understood. It has been
shown that renal vascular endothelial cells are stimulated by
ischemia/reperfusion to express adhesion molecules, such as
intercellular adhesion molecule-1,35,36 P-, and E-selec-
tins,37–39 which may result in the enhanced recruitment and
activation of inflammatory CD4þ T cells during endothelial
transmigration. But there have been no rigorous studies to
date to determine how the effector lymphocytes migrate to
tubulointerstitium. Monocyte chemoattractant protein 1
expression in tubular epithelium has been reported to
increase in renal IRI, correlating with monocyte/macrophage
infiltration in the post-ischemic kidney,40,41 but mostly likely
occurred after stimulation of endothelial and infiltrating
leukocytes presented in ischemic kidneys.26 Our current
findings indicate that pro-IL-16 in the nephron could act as
an initial chemokine for lymphocyte migration to the
tubulointerstitium following exposure to stress or injury. As
we demonstrate in this study, in vitro the pro-IL-16 in TEC
cultures is cleaved into chemotactic mature IL-16 (Figures 1
and 2), which may be due to the activation of caspase-3, as
found in T cells.15 It has been well established that caspase-3
is crucial for cell apoptosis.42 Even though we have not shown
the activation of caspase-3 in this study, there must be a basal
level of caspase-3 activation in TEC cultures, in which
constant activation of antiapoptotic c-FLIP and detectable
apoptosis have been demonstrated in our previous stu-
dies.43,44 Thus, caspase-3 activated under the stress of an in
vitro culture system can cleave the pro-IL-16 protein in TEC
cultures. In mice with ischemic kidneys, the presence of IL-16
protein in urine was observed (Figure 4). Although the
contribution of IL-16 from infiltrating leukocytes to the urine
cannot be excluded, the abundant amount of pro-IL-16
protein in the damaged nephron, in which caspase-3 can be
activated by inflammatory events such as hypoxia,45 can be
released during initial ischemia/reperfusion, which is sup-
ported by reduced staining of pro-IL-16 protein in damaged
tubules (Figure 4).
It has been documented that CD4 is a major receptor for
secreted IL-16,18,46,47 and IL-16 is more active in the
induction of migration of Th1 than Th2.48 In agreement
with the critical role of interferon-g-producing CD4þ Th1
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Figure 9 | Less effectiveness of anti-IL-16 antibody therapy in
lymphocyte-deficient NOD-scid/scid mice. NOD-scid/scid male mice
were subjected to renal ischemia–reperfusion at 40 1C of body
temperature for 60 min and received either anti-IL-16 IgG or control
IgG (in 200ml of saline) through inferior vena cava (IVC) injection. Sera
were collected after 48 h of reperfusion. Kidney function was
determined by measurement of serum creatinine and urea (BUN).
(a) Serum creatinine levels. Data are presented as mean±s.e.m. of 11
mice in each group. P¼ 0.1405 (anti-IL-16 IgG vs control IgG). (b) BUN
level. BUN was measured in the same sera. Data are presented as
mean±s.e.m. P¼ 0.1331 (anti-IL-16 IgG vs control IgG).
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cells in renal IRI as discussed above, neutralization of IL-16,
released from damaged nephron and possibly from infiltrat-
ing leukocytes as well, by monoclonal antibody may result in
limiting Th1 effector cell migration to the tubulointerstitium.
As a result, kidney injury is prevented and, consequently, the
function is preserved, as indicated by the lower levels of
serum creatinine and BUN in the anti-IL-16 antibody-treated
mice (Figure 5). The pathological role of IL-16 in the
development of IRI is further confirmed by demonstration of
resistance to IRI in IL-16 KO mice (Figure 6). So far, how IL-
16 contributes to renal IRI is not completely understood. It
has been hypothesized that its chemotatic activity on effector
lymphocytes, particularly CD4þ T cells, may play a
pathological role in renal IRI. Our data show that, as
compared to WT controls, less migration of CD4þ cells is
found in ischemic kidneys of IL-16-deficient mice (Figure 8),
which is also correlated to less injury in these mice (Figure 6).
Furthermore, in lymphocyte-deficient SCID mice (Table 1,
Figure 7), anti-IL-16 antibody therapy is noted to reduce
certain levels of renal IRI, which may be due to its effect on
the inflammatory responses of remnant lymphocytes, but not
as significantly as seen in B6 mice. Similar to RAG-1
(recombination activating gene 1)-deficient mice as demon-
strated previously,7,49 renal IRI in SCID mice could be mainly
caused by non-lymphocyte inflammatory mediators, such as
C5b-9-mediated tubular cell damage.32 Therefore, in the
absence of a significant role of Th1 cells, the target of IL-16,
the effectiveness of anti-IL-16 antibody therapy is impacted
as expected.
In conclusion, IRI is a primary cause of acute renal failure
in both native kidneys and allografts. There is no specific
therapy to effectively improve the clinical outcome of these
forms of renal injury. Here, we show the renal expression of
IL-16, which can be cleaved to a mature form of IL-16 under
the stress of an in vitro culture system. Neutralization of IL-
16 by anti-IL-16 monoclonal antibody reduces the severity of
renal IRI in a mouse model. These results indicate that renal
IL-16 is a potential therapeutic target for preventing or
reducing renal injury. In addition, the levels of urine IL-16
may be monitored as a biomarker for the severity of renal
injury in both native and transplanted kidneys.
MATERIALS AND METHODS
Animals and cell cultures
C57BL/6 (B6) and Balb/c mice (male, 25 g body weight) were
obtained from the Jackson Laboratory (Bar Harbor, ME, USA);
SCID and IL-16 KO (Balb/c background) mice (male, 25 g body
weight) were provided from the breeding colony in the animal
facility of the Robarts Research Institute or the University of
Western Ontario (London, ON, Canada). All the animals for
experiments were maintained in the animal facility of the University
of Western Ontario. Animal experiments were conducted in
accordance with the Canadian Council on Animal Care guidelines
under protocols approved by the Animal Use Subcommittee at our
institution.
Primary TECs were isolated from the kidney cortex of mice as
described previously.50 Cloned NG1.1 TEC from a B6 mouse was
immortalized with origin-deficient SV40 DNA. Phenotype of TEC
was confirmed by expression of E-cadherin, CD13 (alanine
aminopeptidase), and CD26 (dipeptidyl peptidase). Both primary
and cloned TECs were grown in complete K1 medium as described
previously.43
RT-PCR
IL-16 mRNA in TEC cultures or kidney tissue was analyzed by RT-
PCR kits following the provided protocol (Invitrogen, Carlsbad, CA,
USA). Briefly, total RNA was obtained from cells or tissues using
TRIzol Reagent (Invitrogen), and 5 mg of total RNA was used at
room temperature, followed by PCR amplification (35 cycles) using
IL-16 cDNA-specific primers (sense, 50-AAAAATGGACGCTGC
CAATG and antisense, 50-TTGACCCAGGAGACCAGAAAATC)
and appropriate annealing temperature. PCR products (382 bp size)
were visualized in 1% agarose in tris-acetate-EDTA (TAE) buffer
containing 0.5 mg ml1 of ethidium bromide. Analysis of levels was
semiquantitative compared to GAPDH (glyseraldehyde-3-phosphate
dehydrogenase) mRNA.
Western blot
IL-16 protein in protein extracts of TEC cultures or kidney tissues
was examined by western blot as described previously.43 Briefly,
protein samples (100–150 mg) were fractionated by 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, and then trans-
ferred onto the nitrocellulose membrane. The levels of IL-16
proteins were identified with rabbit polyclonal anti-IL-16 antibody
(clone H-110; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
visualized by an enhanced chemiluminescence assay (Amersham
Pharmacia Biotech, Buckinghamshire, UK). Blots were re-probed
using anti-b-actin IgG (Sigma-Aldrich Canada, Oakville, ON,
Canada) for confirmation of loaded protein in each sample.
Chemotaxis assay
The leukocyte chemotaxis to IL-16 was determined by the
fluorescence-based method with the ChemoTx Disposable Chemo-
taxis System (NeuroProbe, Gaithersburg, MD, USA) as described
previously.51 Briefly, splenocytes from B6 mice were labeled with
calcein AM (5mg ml1; Invitrogen-Molecular Probes, Eugene, OR,
USA) and were adjusted to a final concentration of 3 106 cells ml1.
Protein extract (from 1 mg ml1 to 1 ng ml1) and 10mg ml1 of anti-
IL-16 (clone 14.1) or control IgG (clone UPC-10; Sigma-Aldrich
Canada) were added to each well of a disposable 96-well chemotaxis
chamber (ChemoTx, NeuroProbe) in triplicate, which was then
covered by a polycarbonate filter (pore size, 8mM). The fluorescence-
labeled splenocyte (75 000 cells in 25ml) was placed directly on the top
of the filter on each well, and the chamber was incubated for 4 h
(37 1C and 5% CO2). The cells that migrated into the chamber were
counted by measuring calcein fluorescence in each well in a multi-well
fluorescent plate reader (excitation, 485 nm; emission, 530 nm). The
background control (BC) represented the fluorescence of the mixture
of protein extract and antibody without splenocytes. The maximal
control (MC) was the total fluorescence in the well containing labeled
splenocytes (75 000 cells per well), protein extract, and antibody. The
migration was calculated as migration (%)¼ (fluorescence of
sample–BC)/(MC–BC).
Immunohistochemical analysis
The levels of IL-16 protein in kidney sections were assessed by
a standard immunohistochemical method. Briefly, kidney was
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perfused with PBS before formalin fixation, paraffin embedding,
and sectioning. After deparaffin and rehydration, buffered formalin-
fixed sections were treated with 3% H2O2 in Tris buffer saline (pH
7.4) for 30 min at room temperature to quench endogenous
peroxidase, followed by permeabilization with 0.2% Triton X-100
for 10 min at room temperature. After washing with Tris buffer
saline and blocked with 2% normal goat serum, the sections were
incubated with rabbit polyclonal anti-IL-16 antibody (H-110, 1:200
dilution; Santa Cruz Biotechnology) overnight at 4 1C. The immune
complexes of IL-16 and anti-IL-16 antibody on the tissue sections
were detected using anti-rabbit Ig antibody conjugated with biotin
and visualized using a 3,30-diaminobenzidine peroxidase substrate
kit (Vector Labs, Burlington, ON, Canada).
ELISA
Urinary IL-16 protein levels were measured using commercial
human IL-16 ELISA kits (Antigenix America Inc., Huntington
Station, NY, USA) according to the manufacturer’s protocols. All the
samples were diluted at a 1:1 dilution with Assay Diluent solution
(eBioscience, San Diego, CA, USA) and were examined at least in
triplicate. A standard curve using recombinant cytokine
(0.2–10 ng ml1) was generated for each assay.
Flow cytometric analysis
The expression of surface antigen marker for each lymphocyte
phenotype was determined by flow cytometric analysis. Single cell
suspension of splenocytes from B6 or SCID mice or isolated
infiltrates from ischemic kidneys was stained with the fluorescent
dye-conjugated antibody in 10% normal goat serum at 4 1C for
30 min. After washing with PBS, samples were analyzed with flow
cytometry (Becton Dickinson, Franklin Lakes, NJ, USA) and data
were analyzed using Cell Quest software (BD Biosciences, San Diego,
CA, USA). Fluorescent dye-conjugated anti-TCRb antibody (H57-
597), anti-CD4 antibody (L3T4, RM4-5), anti-CD8a antibody
(Ly-2, 53-6.7), and anti-CD 45R/B220 antibody (RA3-6B2) were
purchased from BD Biosciences.
Renal IRI model and antibody treatment
All different strains of mice were anesthetized with ketamine
(100 mg kg1) and Rompun (20 mg kg1), and exposed kidneys
through a flank incision. Ischemia was induced in the left kidney by
clamping renal pedicles at 32 1C of body temperature for 45 min for
B6 mice, 34 1C of body temperature for 60 min for Balb/c or IL-16
KO mice, or 40 1C for 60 min for SCID mice. Meanwhile, the anti-
human IL-16 (clone 14.1) or control IgG (clone UPC-10) (100 mg in
200ml of saline) was delivered to the kidney by inferior vena cava
injections. After the clamps were released, reperfusion of the kidneys
was confirmed visually and the right kidney was removed. Renal
tissues and sera were harvested at 48 h after ischemia. The uni-
nephrectomized mice were included as sham-operated controls.
Determination of renal function and injury
The function of kidney was determined by serum creatinine and
BUN, which were measured by a Jaffe reaction method with an
automated CX5 clinical analyzer (Beckman Instruments, Fullerton,
CA, USA) in the Pathology core laboratory (London Health Sciences
Centre, London, ON, Canada). Histological assessment of tubular
injury in kidney sections was performed in a blinded fashion.
Formalin-fixed and paraffin-embedded sections (5mm thickness)
were stained by the periodic acid-Schiff method. The percentage of
damaged tubule (necrosis and vacuolization) in total number of
tubules was counted in each view at  400 magnification and was
averaged from at least 20 nonoverlapping fields for each kidney.
Statistical analysis
One-way analysis of variance or t-tests (one-tailed distribution) in
Statview software (SAS Institute, Cary, CA, USA) were used as
appropriate for comparisons between groups. Data were collected
from individual experiment or mouse in each study for statistical
analysis. A P-value of p0.05 was considered significant.
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